Reviewing the thoroughness of human safety testing for succinate dehydrogenase inhibitors: fluopyram as a case study

• by Kim Z. Travis, Rémi Bars, Helen Tinwell

• February 13, 2026

2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

• October 15, 2026

• 1 min

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

• October 15, 2026

• 1 min

2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.

• October 15, 2026

• 1 min